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Cystatin, a natural cysteine protease inhibitor, has strong antileishmanial activity, which is due to its
potential to induce nitric oxide (NO) generation from macrophages. Cysteine protease-inhibitory activity and
NO-up-regulatory activity correspond to different regions, as revealed by the dissection of cystatin cDNA into
nonoverlapping fragments. By using synthetic overlapping peptides, the NO-up-regulatory activity was found
to be confined to a 10-mer sequence. In addition to having reasonable inhibitory effects on amastigote
multiplication within macrophages (50% inhibitory concentration, 5.2 g/ml), 97 and 93% suppression,
respectively, of liver and spleen parasite burdens was achieved with the 10-mer peptide at a dose of 0.5 mg/kg
of body weight/day, given consecutively for 4 days along with a suboptimal dose of gamma interferon in a 45-day
mouse model of visceral leishmaniasis. Peptide treatment modulated the levels of cytokine secretion by infected
splenocytes, with increased levels of interleukin-12 and tumor necrosis factor alpha and increased inducible
NO synthase production, and also resulted in resistance to reinfection. The generation of a natural peptide
from cystatin with robust immunomodulatory potential may therefore provide a promising therapeutic agent
for macrophage-associated diseases.
The key pathogenic event in the fatal disease of visceral
leishmaniasis is the harboring of the causative parasite Leish-
mania donovani within the phagolysosomes of the macro-
phages of the liver, spleen, and bone marrow. Presently, there
is no widely available vaccine against leishmaniasis and che-
motherapy remains the major medical mode of managing the
disease. However, the chemotherapeutic cure of leishmaniasis
is largely dependent upon the development of an effective
immune response that activates the macrophages to produce
toxic nitrogen and oxygen intermediates to kill the parasites.
The parasite itself is known to suppress this process by down-
regulating the production of such reactive species within the
macrophages. Consequently, a potential therapy for leishman-
iasis would be to up-regulate such innate immune responses
mediated by the parasite infected-macrophages themselves.
Leishmania expresses various molecules believed to contrib-
ute to its ability to infect and proliferate in mammals. Cathep-
sin L-like cysteine protease (CP) is one such molecule, which is
predominantly expressed and active in the amastigote form
and to a lesser extent in metacyclic promastigotes (20). This
observation, together with the fact that Leishmania cannot
grow within macrophages in the presence of CP inhibitors,
suggests that CPs are necessary for successful intracellular
parasitism (19). Large amounts of parasite-derived CPs have
also been associated with the extracellular milieu of Leishma-
nia-infected mouse lesions (17) and are reported to stimulate
an increase in the expression of interleukin-4 (IL-4) and IL-1
(9), driving the differentiation of the CD4 precursors towards
the Th2 phenotype and thus favoring the proliferation of the
parasite. We have previously demonstrated that cystatin, a
natural cysteine protease inhibitor, can synergize with sub-
threshold concentrations of gamma interferon (IFN-) in in-
ducing favorable cytokine responses and the generation of
nitric oxide (NO), resulting in the elimination of parasite in-
fection in experimental visceral leishmaniasis (6). Cystatin can
stimulate NO production in IFN--activated murine macro-
phages (27), and this effect may be unrelated to its inhibition of
cysteine protease, since the irreversible and structurally unre-
lated cysteine protease inhibitor E64 did not have any effect on
activated macrophages (26).
We therefore characterized the NO-stimulatory domain in
cystatin with a view to deciphering the minimal peptide se-
quence involved in NO generation to develop an immunopo-
tent biopeptide. We used three nonoverlapping recombinant
proteins spanning the sequences of the N-terminal region, the
intermediate region, and the C-terminal region to demonstrate
the presence of the up-regulatory activity in the N-terminal
end. Using overlapping synthetic peptides derived from this
potent region, we also demonstrated that apart from being able
to generate NO with subthreshold amounts of IFN-, a 10-mer
peptide is able to induce a protective Th1 response to L.
donovani infection in susceptible mice. Finally, the therapeutic
relevance of these data, along with a plausible mechanism for
NO stimulation, is discussed.
MATERIALS AND METHODS
NO production, parasite killing, and in vivo infection. The origin, in vivo
passage, and in vitro propagation of the L. donovani isolate (MHOM/IN/1983/
AG83) were as reported previously (25). Peritoneal macrophages (BALB/c)
were cultured as previously described (25). After the treatment of cultures with
various agents, the supernatants of the cell cultures were assayed for nitrite
production by using the Greiss assay (6). Adherent macrophages were infected
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with stationary-phase L. donovani promastigotes at a 10:1 parasite/cell ratio.
Infection was allowed to proceed for 4 h, and the cells were washed to remove
excess parasites, as described previously (6). After treatment with various agents
at 37°C, the number of parasites per 100 macrophages was determined by
staining with Giemsa. For in vivo infection, mice (BALB/c; 20 to 25 g) were
injected via the tail vein with 107 promastigotes. At day 10 after the injection of
parasites, cystatin and cystatin-derived peptides were injected into the tail veins
in various doses for 4 consecutive days. Forty-five days after infection, mice were
examined for parasite burdens by counting the number of amastigotes in the
Giemsa-stained imprints of livers and spleens. Organ parasite burdens, expressed
as Leishman-Donovan units (LDU), were calculated as follows: number of amas-
tigotes per 1,000 cell nuclei  organ weight (g) (21).
Cytokine analysis. Splenocyte cultures were prepared from infected mouse
spleens every 15 days after infection as described previously (25). After stimu-
lation with 20 g/ml soluble leishmanial antigen for 48 h, the supernatants of the
cell cultures (4  106 cells/ml) were assayed for IL-12, tumor necrosis factor
alpha (TNF-), and IL-10 by using an enzyme-linked immunosorbent assay kit
(BD Biosciences, San Jose, CA). mRNA profiles for these cytokines along with
-actin as an internal control were analyzed by reverse transcription (RT)-PCR.
The reverse transcription of 1 g of RNA was performed with the Superscript
one-step RT-PCR system according to the protocol of the manufacturer (In-
vitrogen, New Delhi, India). Oligonucleotide primers for these cytokines were
selected from published cDNA sequences. After the appropriate number of PCR
cycles, the amplified DNA was separated by 2% agarose gel electrophoresis and
visualized by ethidium bromide staining.
Analysis of iNOS expression by RT-PCR and immunoblotting. RT-PCR was
performed to determine the mRNA profile corresponding to inducible NO
synthase (iNOS), along with -actin as an internal control. For immunoblot
analysis, 20 g of whole-cell extracts was resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), electroblotted onto a nitrocel-
lulose membrane, and probed with murine anti-iNOS antibody (Transduction
Laboratories, Lexington, KY) and proteins were detected by using an ECL kit
(Amersham Biosciences, Arlington Heights, IL) with horseradish peroxidase-
conjugated anti-rabbit immunoglobulin G (1:2,000 dilution).
Saturation of cystatin-inhibitory sites by carboxymethylated papain. For in-
activation, 1 mg of papain was kept for 5 min in a solution containing 0.1 M
phosphate buffer (pH 6.8), 1 mM EDTA, 0.1% Brij 35, and 2 mM dithiothreitol
and incubated for 1 h with 10 mM iodoacetic acid at 37°C in the dark. The excess
alkylating reagent was removed by gel filtration through a PD10 column (Am-
ersham Biosciences). The completion of inactivation was indicated by a complete
loss of enzymatic activity against the fluorogenic substrate Z-Phe-Arg-4-methyl-
7-coumarin (Z-Phe-Arg-NHMec). Carboxymethylated papain complexes were
made by mixing chicken cystatin, stefin, or T-kininogen with a large excess of
papain (10:1) at 37°C over a period of 45 min. The saturation of inhibitory sites
was checked by measuring the residual activity of native papain on the Z-Phe-
Arg-NHMec substrate in the presence or absence of the saturated inhibitor.
Effect of cystatin and cystatin-derived peptides on papain. The effect of cys-
tatin and cystatin-derived peptides on papain was determined by measuring the
equilibrium constants for dissociation (Ki) of complexes between cystatin and
papain, as described by Hall et al. (14). Briefly, continuous-rate assays with
Z-Phe-Arg-NHMec were carried out in 100 mM sodium phosphate buffer, pH
6.0, containing 1 mM dithiothreitol and 2 mM EDTA (22). Ki were measured
directly in equilibrium inhibition experiments according to the method of Hand-
erson (16), and the obtained Ki were corrected for substrate competition by using
the Ki of 42 M for papain (28).
Anti-cystatin and anti-peptide antibodies. The peptide was first conjugated to
keyhole limpet hemocyanin according to the method of Gullick (12), which
yielded a conjugate of 0.24 mol/mg of keyhole limpet hemocyanin. Antibodies
to cystatin-peptide conjugates were raised in New Zealand rabbits as described
previously (2). Anti-cystatin antibodies were separated from sera according to
the method of Hall et al. (15), whereas anti-peptide antibodies were affinity
purified by the method of Edwards et al. (7).
Molecular cloning, expression, and purification of cystatin-derived recombi-
nant peptides. The nonoverlapping fragments of cystatin cDNA encoding amino
acid sequences corresponding to the NH2-terminal region (amino acid [aa]
residues 1 to 28), the intermediate region (aa residues 29 to 72), and the
COOH-terminal part of the molecule (aa residues 73 to 116) were amplified as
oligonucleotides containing BamHI and XhoI overhangs by using sequence-
specific primers from chicken cystatin cDNA (a kind gift from Rita Collela,
Bureau of Biological Research, NJ). These amplified fragments were cloned into
the BamHI-XhoI site of a prokaryotic expression vector, pGEX-5X-2 (Amer-
sham Biosciences), and Escherichia coli strain BL21(DE3) (Novagen, San Diego,
CA) was transformed with the pGEX-5X-2-GST constructs. Transformed E. coli
was grown in Luria-Bertani and induced with isopropyl--D-thiogalactopyrano-
side (IPTG), and recombinant glutathione S-transferase (GST) fusion proteins
were purified by a standard procedure using reduced glutathione beads.
Electrophoresis and immunoblotting. The cystatin-derived recombinant pro-
teins were analyzed on a 10% SDS-PAGE gel under reducing conditions and
immunoblotted with anti-cystatin or anti-peptide antibody according to the
method described above.
Statistical analysis. The statistical significance of differences between any two
groups was analyzed by using two-tailed Student’s t test.
RESULTS
Resolution of visceral leishmaniasis by cystatin through NO
up-regulation. Although a suboptimal dose of IFN- was re-
quired for cystatin to induce NO production in mouse perito-
neal macrophages (Fig. 1A), in an in vivo situation, IFN- was
not a prerequisite. Thus, peritoneal macrophages isolated from
BALB/c mice given intravenous (i.v.) injections of cystatin
produced significantly higher levels of NO2
 than those from
mice that did not receive cystatin (Fig. 1B). In a mouse model
of visceral leishmaniasis, the administration of cystatin at a
dose of 20 mg/kg of body weight/day for 4 consecutive days
beginning 10 days after infection could cause a marked sup-
pression of spleen parasite burdens (mean  standard devia-
tion [SD] log10 number of LDU, 1.17 0.17, compared to 2.47
0.05 for the untreated controls; P 	 0.001). However, when a
suboptimal dose of IFN- (5  105 U/kg/day) was coadminis-
tered with the cystatin, a much more pronounced effect (com-
plete suppression of the spleen parasite burdens) was obtained
at a much lower dose of cystatin of 5 mg/kg/day (Fig. 1C). The
coadministration of 0.1 mg/kg/day of 2-amino-5,6-dihydro-6-
methyl-4H-1,3-thiazine (AMT), an inhibitor of iNOS, caused a
reversal of the parasite-suppressive effect, suggesting the in-
volvement of NO in cystatin-mediated antileishmanial activity.
In the in vitro situation of amastigote multiplication within
macrophages also, the inhibitory effect of cystatin in the pres-
ence of 100 U/ml of IFN- (50% inhibitory concentration, 4.3
g/ml) was abolished by treatment with 10 M AMT (Fig.
1D). The in vivo and in vitro effects of cystatin in the presence
of AMT were also reflected in the iNOS mRNA expression
pattern analyzed by RT-PCR and the iNOS levels analyzed by
Western blotting, as shown in Fig. 1E and F, respectively. It
may be mentioned that cystatin plus IFN- did not have any
influence on the in vitro proliferation of L. donovani promas-
tigotes.
Regions for NO up-regulation and cysteine protease inhibition.
In order to determine whether the cysteine proteinase-inhibi-
tory region overlaps with the NO-stimulatory region, cystatin
was saturated with inactivated papain. When examined, com-
plexed cystatin in IFN--activated macrophages was found to
have NO-generating abilities comparable to those of the free
form (Fig. 2). Other members of the cystatin superfamily,
human stefin B and T-kininogen, when complexed with re-
duced papain also generated nitrite levels which were compa-
rable to those generated by the free inhibitors after 48 h of
incubation, while aprotinin, an unrelated protease inhibitor,
did not show any induction of NO. These results indicate the
presence of a distinct NO-stimulatory domain unrelated to
protease-inhibitory activity in cystatin and related compounds.
Domain of cystatin involved in NO up-regulation. To gain
insight into the region of cystatin responsible for NO up-reg-
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ulation, the cDNA of cystatin was dissected into three non-
overlapping fragments corresponding to Cst I, Cst II, and Cst
III and representing the NH2-terminal region (aa residues 1 to
28); the intermediate region (aa residues 29 to 72) comprising
the conserved QLSVG segment, known to play a central role in
the cysteine proteinase-cystatin interaction; and the COOH-
terminal part of the molecule (aa residues 73 to 116), respec-
tively. By using sequence-specific PCR primers, the respective
FIG. 1. Antileishmanial activity of cystatin through the generation of NO. (A) NO production by peritoneal macrophages (106/ml) incubated
for 48 h in culture medium with cystatin (Cys; 5  107 M), L. donovani (L.d.; macrophage/parasite ratio, 1:10), IFN- (100 U/ml), IFN- plus
L. donovani, IFN- plus cystatin, and IFN- plus cystatin plus L. donovani. (B) Generation of NO in peritoneal macrophages isolated from mice
which received i.v. injections of either cystatin (5 mg/kg/day) or IFN- (104 U/mouse) or both for 4 consecutive days. Macrophages were isolated
10 h after the last injection. Data represent the means  SD of results from three experiments. AMT (5 mg/kg/day) was used along with cystatin
and IFN- in a separate experiment. (C) In vivo antileishmanial activity of cystatin and cystatin plus IFN-. Mice were challenged with 107
promastigotes, and after 10 days of infection, they were treated with various i.v. doses of cystatin with or without IFN- (104 U/mouse) daily for
4 consecutive days. Spleen parasite burdens were determined 45 days after infection and are expressed as the mean log10 number of LDU  SD
for six animals. In another set of experiments, AMT (5 mg/kg/day) was used along with cystatin and IFN-. The log10 number of LDU in the
infected control was 2.8  0.08. (D) In vitro antileishmanial activity. Macrophages were infected with L. donovani promastigotes, excess parasites
were washed off, and cells were treated with graded concentrations of cystatin with or without IFN- (100 U/ml) for 48 h at 37°C. AMT (10 M)
was given along with cystatin plus IFN- in a separate set of experiments. The parasites inside each macrophage were counted. The infected
controls had 7.22  0.65 amastigotes/macrophage. The nature of iNOS was determined by RT-PCR analysis of the mRNA transcript (E) and by
Western blot analysis of the protein levels (F) corresponding to various treatment regimens. Band intensities were analyzed by densitometry (E1
and F1).
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fragments were picked up from the cDNA and ligated into a
prokaryotic expression vector, which allowed the production of
large amounts of the respective polypeptides as GST fusion
proteins in E. coli. Following IPTG induction of the bacteria
transformed with the respective constructs, an additional band
of 
30 kDa (27 kDa from GST and 
3 kDa from the respec-
tive nonoverlapping polypeptides of cystatin) was obtained
upon SDS-PAGE (Fig. 3A, lanes 2, 4, and 6), whereas the
lysate of induced bacteria harboring the vector alone showed a
GST band of 27 kDa (Fig. 3A, lanes 1, 3, and 5). That GST
fusion did not interfere with the native forms of the respective
polypeptides was evidenced by Western blot analysis of the
fusion constructs with anti-cystatin antibody (Fig. 3B). Analysis
by PAGE showed that the various recombinant polypeptides
purified from bacterial lysates by affinity chromatography using
GST purification columns produced single bands correspond-
ing to a molecular mass of
30 kDa (Fig. 3C), and anti-cystatin
antibody was found to react with single bands from these
recombinant polypeptides (Fig. 3D, lanes 2 to 4). When these
recombinant polypeptides were analyzed for their NO-gener-
ating capabilities, Cst I showed the maximum level of NO
induction (12 nmol/106 cells at 0.1 nM concentration) while Cst
II and Cst III had no significant effect (Fig. 3E). This result was
also reflected in the iNOS mRNA expression pattern (Fig. 3F)
and protein level (Fig. 3G). When these recombinant peptides
were assessed for their cysteine protease-inhibitory activity
with papain, only the intermediate fragment Cst II inhibited
papain, with a Ki of 900 nM. Both Cst I and Cst III exhibited
1,000-fold-weaker inhibition than the whole molecule, indi-
cating thereby that the N-terminal region of cystatin is not
involved in cysteine protease inhibition but has a role to play in
NO up-regulation.
Cystatin-derived immunomodulatory peptide exhibiting anti-
leishmanial activity. To determine whether the region of the
N-terminal domain of cystatin with NO-generating capability
could be narrowed down to a minimal amino acid sequence, a
set of six synthetic overlapping peptides (compounds 1 to 6) of
8 amino acids each, spanning the entire 28 aa of Cst I, were
assessed. Maximum NO-generating ability was found to be
associated with compound 4 (Fig. 4A). Further, by using four
overlapping peptides of 10 aa (compounds A to D) covering
the 8 amino acids of compound 4, a 10-mer region (compound
B) from positions 11 to 20 of Cst I was found to be the domain
responsible for NO-stimulatory activity (Fig. 4B), and the NO-
stimulatory activity of this region was comparable to that of the
whole cystatin molecule. The level of NO2
 release by macro-
phages progressively increased with increasing concentrations
of compound B up to 1 M, when the level of release reached
a maximum (Fig. 4C). In order to ascertain the specificity of
this compound, a rabbit polyclonal antibody against this 10-
mer region was raised. The presence of 5 g/ml of the anti-
peptide antibody could almost totally abolish the NO genera-
tion at concentrations of compound B as high as 5 M (Fig.
4C). We then examined the efficacy of compound B against the
intracellular growth of amastigotes within macrophages. L.
donovani-infected cultures were treated with graded concen-
trations of compound B, ranging from 0.1 to 5 M, in the
presence of subthreshold concentrations of IFN-. As shown in
Fig. 4D, compound B exhibited profound antileishmanial ac-
tivity, with a 50% inhibitory concentration of 0.52 g/ml. Both
AMT, a specific iNOS inhibitor, and anti-peptide antibody
could cause a reversal of the antileishmanial effect, suggesting
thereby that the antileishmanial effect of compound B may be
correlated with an increased production of NO.
Effect of the cystatin-derived 10-mer peptide on experimen-
tal leishmaniasis. The efficacy of the 10-mer peptide for the
treatment of visceral leishmaniasis in vivo was determined with
a mouse model. BALB/c mice were infected i.v. with L. dono-
vani AG83. Animals were given i.v. injections of graded doses
(0.01 to 1.0 mg/kg/day) of the peptide along with a constant
dose of 104 U of IFN- daily for 4 consecutive days beginning
10 days after infection, and infection was allowed to proceed
for 45 days. The degree of leishmanicidal potency of the pep-
tide was assessed in terms of liver and spleen parasite burdens.
Reductions of 93 and 95% in liver and spleen parasite burdens,
respectively, were obtained at a dose of 0.5 mg/kg/day (Fig.
5A). In the placebo-treated infected controls, high parasite
burdens were present in livers (log10 number of LDU, 3.41 
0.32) and spleens (log10 number of LDU, 2.32  0.21). This
was also the case in animals receiving anti-peptide antibody in
conjunction with compound B treatment. The reinfection of
cured animals after 45 days resulted in only a slight and tran-
sient increase in organ parasite burdens, suggesting the possi-
ble development of protective immunity (Fig. 5B). To ascertain
whether compound B-treated mice also controlled the infec-
tion by a NO-dependent mechanism, AMT (5 mg/kg/day) was
administered 1 week after reinfection. Within 3 to 4 days of
AMT administration, the organ parasite burdens started in-
creasing. The infections were under control again after AMT
was withdrawn (Fig. 5B).
Effect of cystatin on cytokine production. To gain insight
into the type of immunological response in L. donovani-in-
fected mice after peptide therapy, levels of transcription of
IL-10, IL-12p40, and TNF- mRNA in isolated splenocytes
were determined 45 days after infection. There was a high level
of IL-10 in infected, untreated controls and a low level of
expression of transcripts for IL-12 and TNF- (Fig. 5C). In
contrast, high levels of IL-12 and TNF- expression and a very
low level of IL-10 expression in infected, cystatin-treated cells
FIG. 2. Up-regulation of nitrite release by members of the cystatin
superfamily complexed with papain. Papain was inactivated by reduc-
tion and alkylation. Inactivation was indicated by the complete loss of
enzyme activity. The carboxymethylated papain (105 M) was then
mixed at 37°C for 45 min with 106 M chicken cystatin, human stefin
B, or T-kininogen. The free form or saturated forms were then intro-
duced into the culture medium for 48 h before the nitrite measure-
ment. Data represent the means  SD of results from three experi-
ments.
VOL. 51, 2007 IMMUNOMODULATORY PEPTIDE IN LEISHMANIASIS 1703
as well as cystatin–IFN--treated cells were detected (Fig. 5C).
iNOS was also found to be up-regulated in infected, cystatin-
treated cells and cystatin–IFN--treated cells (Fig. 5D). Levels
of transcripts for various cytokines and iNOS after peptide
therapy and after peptide–IFN- therapy were found to be
comparable to those in infected, cystatin-treated cells and
those in cystatin–IFN--treated cells, respectively (Fig. 5C and
D). To determine the specificity of peptide therapy, we admin-
istered 500 g of anti-peptide antibody along with peptide–
IFN- to L. donovani-infected mice. The anti-peptide antibod-
ies greatly reduced the level of peptide-mediated iNOS in
splenocytes as well as Th1 cytokine induction at the mRNA
level (Fig. 5C and D). The therapeutic effect of the 10-mer
cystatin-derived peptide may be attributed to the up-regulation
of iNOS resulting from the up-regulation of Th1 cytokines.
DISCUSSION
Cystatins represent a widely distributed superfamily of cys-
teine protease-inhibitory proteins. Chicken egg white cystatin
has a molecular weight of approximately 13,000 and binds
tightly to members of the papain family of cysteine proteases.
The human analog is cystatin C, and like the other members of
the cystatin family, it is comprised of one nonglycosylated
120-residue polypeptide chain (11). It is ubiquitous in human
tissue and body fluid (1) and efficiently inhibits endogenous
FIG. 3. Identification of the NO-stimulatory domain of cystatin. (A) Three nonoverlapping fragments representing the N-terminal (Cst I, aa
1 to 28), the intermediate (Cst II, aa 29 to 72), and the C-terminal (Cst III, aa 79 to 116) domains were cloned into a prokaryotic expression vector
(pGEX-5X-2) and expressed as GST fusion proteins. Lanes 2, 4, and 6 show the Coomassie-stained SDS-PAGE gel of GST fusion proteins (
30
kDa) with Cst I, Cst II, and Cst III, respectively, whereas lanes 1, 3, and 5 show the induced bacterial lysate. (B) Corresponding Western blot
analysis using polyclonal anti-cystatin antibody. The purified recombinants as GST fusion proteins (lane 1, recombinant GST; lane 2, GST-Cst I;
lane 3, GST-Cst II; and lane 4, GST-Cst III) were separated on a 10% SDS-PAGE gel (C) and immunoblotted with polyclonal anti-cystatin
antibody (D). (E) Macrophages were incubated with graded concentrations of recombinant GST fusion products of Cst I, Cst II, and Cst III along
with a suboptimal dose of IFN- (100 U/ml) for 48 h, and the release of NO2
 was quantified. Data are means  SD of results from three
experiments. The nature of iNOS expression was also determined by RT-PCR analysis of the mRNA transcript levels (F) and by Western blotting
for analysis of protein levels (G) in response to 1  107 M cystatin (Cys) and various recombinants as GST fusion peptides, along with 100 U
of IFN-/ml. Band intensities were analyzed by densitometry (F1 and G1). Cys II and Cys III, Cst II and Cst III.
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cysteine proteases such as cathepsins B, H, L, and S. These
proteases, found in all species of Leishmania, play a dominant
role in parasite virulence, the modulation of the host’s immune
response, and parasite differentiation. Hence, inhibitors that
would efficiently target the cysteine proteases of the parasite,
while maintaining some selectivity distinguishing them from
the homologous host enzyme, would be ideal drug leads. Cys-
tatin C has also been shown to exhibit antiviral functions, as
suggested from experiments done with polio, herpes simplex,
and corona virus-infected cell lines (3, 5). We previously elu-
cidated the dual role of cystatin of suppressing the functional
differentiation of Th2 type CD4 T cells, leading to the aug-
mentation of the Th1 response, and up-regulating NO, result-
ing in the elimination Leishmania parasites in both in vitro and
in vivo murine models of visceral leishmaniasis (6). In the
present work, we have confirmed the efficacy of cystatin along
with a suboptimal dose of IFN- against experimental visceral
leishmaniasis in BALB/c mice, with effects involving an up-
regulation of NO and a favorable T-cell response. These effects
could be reversed by AMT (an iNOS-specific inhibitor), re-
flecting thereby that increased microbicidal activity was at-
tained via a nitrogen-dependent mechanism involving the in-
duction of iNOS. It has been a well-established fact that NO
produced by cytokine-activated murine macrophages exhibits
microbicidal action during intracellular infections (23). The
ability of cystatin to generate NO from stimulated macro-
phages was unaffected even when the cysteine protease-inhib-
itory site was blocked with reduced papain. Human stefin B
and T-kininogen, members of the cysteine protease inhibitor
family, also demonstrated the same biological ability, while
aprotinin, an unrelated protease inhibitor, exhibited no such
action, indicating that the NO-inducing effect is unrelated to
the protease-inhibitory effect. An appreciable amount of work
has been devoted to the biochemical characterization of the
cysteine protease-inhibitory function of cystatin (18, 13). Based
on such findings, peptide segments derived from consensus
FIG. 4. Minimal peptide sequence with NO-stimulatory potential and its antileishmanial activity. (A) Macrophages were incubated with
overlapping synthetic peptides (8-mer) derived from Cst I along with IFN- (100 U/ml), and NO2
 release was quantified. (B) NO2
 release from
macrophages in response to overlapping 10-mer peptides containing the most potent 8-mer peptide in terms of NO production was measured.
(C) Dose response curves for various concentrations of compound B in combination with IFN- (100 U/ml) representing the release of NO2
 by
macrophages in the presence or absence of either anti-compound B antibody or AMT (10 M). (D) Infected macrophages were treated with
graded concentrations of compound B in combination with IFN- (100 U/ml) in the presence or absence of either anti-compound B antibody or
AMT (10 M). Infected controls contained 7.14  0.69 amastigotes/macrophages. Data are means  SD of results from three experiments.
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sequences of the inhibitory site of cystatin have been used as
models to design and develop specific substrates and selective
inhibitors of cysteine proteinases and have been shown to exert
activity against pathogens like Porphyromonas gingivalis (4, 28).
The characterization of the chicken cystatin-encoding gene
has revealed the gene to be 
 2.4 kb in length and to contain
three exons, two introns, and two polyadenylation signals. We
made use of recombinantly expressed fragments of chicken
cystatin to identify and characterize the region for NO gener-
ation in activated macrophages. The aim was to design an
immunostimulatory peptide moiety that would not only mini-
mize drug doses per se but also be used as a natural immuno-
modulator in macrophage-related disorders requiring a NO-
promoting response. A total of three separate fragments (
30
aa each) spanning the entire length of functional cystatin were
expressed as fusion proteins, purified, and used to test their
efficacy in generating NO in activated macrophages. The N-
terminal fragment (Cst I), which did not possess the well-
documented cysteine protease-inhibitory site (18), was found
to be the most potent of the three fragments in terms of NO
generation. Further analysis of the NO-up-regulatory response
by using a minimal 10-mer peptide synthetically derived from
this region revealed NO generation capability both in vitro and
in vivo. When assessed for leishmanicidal potential, the 10-mer
peptide corresponded to a pattern of elevated iNOS transcript
levels in parallel with a disease-regressing Th1 cytokine (IL-12
FIG. 5. Effect of compound B treatment on visceral infection in BALB/c mice. (A) Various doses of compound B ranging from 0.05 to 1
mg/kg/day were given i.v. along with IFN- (104 U/mouse) for 4 consecutive days beginning 10 days after infection. The parasite burdens in livers
and spleens were then determined at 45 days after infection. Anti-peptide antibody was given along with compound B and IFN- in a separate set
of experiments. (B) The course of visceral reinfection was studied by i.v. administration of 107 promastigotes into naı¨ve, age-matched BALB/c mice
and cured (1-mg/kg/day-compound B-treated) mice. In one group of cured mice, AMT (5 mg/kg/day) was i.v. administered 1 week after reinfection
for 2 weeks. Determining liver and spleen parasite burdens, expressed as the log10 numbers of LDU, allowed for the monitoring of the progression
of infection in all the cases. Results are from three experiments and indicate the means  SD for 5 to 7 mice at each time point. Ab, antibody.
(C and D) Cytokine profiles of L. donovani-infected mice as analyzed by RT-PCR. The levels of expression of IL-10, IL-12, TNF-, iNOS, and
-actin mRNA by spleen cells of infected mice treated i.v. with the peptide and/or IFN- in the presence or absence of anti-peptide antibody were
determined and compared to those by spleen cells of mice receiving cystatin and IFN- treatment. RT products were visualized by ethidium
bromide staining. RNA samples were obtained from five mice in each group. Results shown are representative of those for five separate samples.
-Actin expression levels were used as controls for RNA content and integrity. Band intensities were analyzed by densitometry (C1 and D1).
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and TNF-) expression pattern, thereby suppressing the amas-
tigote proliferation not only in infected peritoneal macro-
phages but also in a 45-day murine model of visceral leishman-
iasis as effectively as the whole molecule. This 10-mer peptide
mimicked the effect of the whole cystatin molecule both in
terms of NO up-regulation and antileishmanial action, as this
effect was completely reversed in the presence of the peptide-
specific antibody, which held true for the whole cystatin mol-
ecule as well. Taken together, the present study identifies the
functional domain of cystatin that holds promise for the design
of an immunomodulatory biopeptide-based therapy for vis-
ceral leishmaniasis and similar macrophage-associated dis-
eases which involve a down-regulation of NO. It may be men-
tioned in this regard that the expression of iNOS and the
consequent production of NO have been shown to correlate
with leishmaniasis resistance in a murine model as well as in
human patients (10). Moreover, several other recent reports
suggest an antileishmanial function of iNOS in human leish-
mania infection in vivo (8, 24).
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